09/09/15 - 01:01 AM EDT
The Santhera drug, Raxone, is the first approved treatment for Leber hereditary optic neuropathy (LHON), which affects approximately 10,000 patients in Europe.
09/08/15 - 04:41 PM EDT
Four biotech companies announced important clinical trials results Tuesday at market close.
09/08/15 - 12:12 PM EDT
Sell-side cheerleading on behalf of their employer's banking clients has become such a standard practice that anything remotely bearish is news.
09/03/15 - 06:23 AM EDT
Biotech columnist Adam Feuerstein answers readers' questions about health care.
09/03/15 - 06:01 AM EDT
The signal of activity Sage Therapeutics sees with SAGE-547 in essential tremor may turn out to be real or a mirage.
09/01/15 - 07:27 AM EDT
Among all U.S.-listed biotech stocks, regardless of market cap, only 68 companies managed to end August with higher stock prices, while 267 biotech stocks lost ground.
08/31/15 - 06:01 AM EDT
Acquiring Scioderm gives Amicus another late-stage orphan disease drug expected to have pivotal trial data in the first half of next year.
08/27/15 - 12:45 PM EDT
Approving both the Biomarin and Sarepta drugs for Duchenne muscular dystrophy is the most politically expedient decision the FDA can make.
08/25/15 - 07:38 AM EDT
Last night, I exchanged emails with a number of investors who run dedicated health care funds. I wanted to know how they navigated Monday's market selloff.
08/24/15 - 12:43 PM EDT
The iShares Nasdaq Biotechnology Index (IBB), the most closely followed biotech sector index, is down less than 1% after a deep plunge at Monday's open.